149 related articles for article (PubMed ID: 30820931)
1. Cancer risk following post-transplant lymphoproliferative disorders in solid organ transplant recipients.
Mahale P; Engels EA; Lynch CF; Morton LM
Br J Haematol; 2019 Jul; 186(2):347-351. PubMed ID: 30820931
[No Abstract] [Full Text] [Related]
2. Post-transplantation lymphoproliferative disorders arising in solid organ transplant recipients are usually of recipient origin.
Chadburn A; Suciu-Foca N; Cesarman E; Reed E; Michler RE; Knowles DM
Am J Pathol; 1995 Dec; 147(6):1862-70. PubMed ID: 7495309
[TBL] [Abstract][Full Text] [Related]
3. Treatment and outcomes in classic Hodgkin lymphoma post-transplant lymphoproliferative disorder in children.
Twist CJ; Hiniker SM; Gratzinger D; Gutkin PM; Merriott DJ; Iagaru A; Link MP; Donaldson SS
Pediatr Blood Cancer; 2019 Aug; 66(8):e27803. PubMed ID: 31062898
[TBL] [Abstract][Full Text] [Related]
4. Cancer-attributable mortality among solid organ transplant recipients in the United States: 1987 through 2014.
Noone AM; Pfeiffer RM; Dorgan JF; Magder LS; Bromberg JS; Lynch CF; Morris CR; Pawlish KS; Engels EA
Cancer; 2019 Aug; 125(15):2647-2655. PubMed ID: 31034602
[TBL] [Abstract][Full Text] [Related]
5. Survival among solid organ transplant recipients diagnosed with cancer compared to nontransplanted cancer patients-A nationwide study.
Benoni H; Eloranta S; Ekbom A; Wilczek H; Smedby KE
Int J Cancer; 2020 Feb; 146(3):682-691. PubMed ID: 30919451
[TBL] [Abstract][Full Text] [Related]
6. Incidence and outcomes of primary central nervous system lymphoma in solid organ transplant recipients.
Mahale P; Shiels MS; Lynch CF; Engels EA
Am J Transplant; 2018 Feb; 18(2):453-461. PubMed ID: 28805292
[TBL] [Abstract][Full Text] [Related]
7. Donor Monoclonal Gammopathy May Cause Lymphoproliferative Disorders in Solid Organ Transplant Recipients.
Felldin M; Ekberg J; Polanska-Tamborek D; Hansson U; Sender M; Rizell M; Svanvik J; Mölne J
Am J Transplant; 2016 Sep; 16(9):2676-83. PubMed ID: 27575725
[TBL] [Abstract][Full Text] [Related]
8. Management of posttransplant lymphoproliferative disorders following solid organ transplant: an update.
Dierickx D; Tousseyn T; De Wolf-Peeters C; Pirenne J; Verhoef G
Leuk Lymphoma; 2011 Jun; 52(6):950-61. PubMed ID: 21338285
[TBL] [Abstract][Full Text] [Related]
9. Donor or recipient origin of posttransplant lymphoproliferative disorders following solid organ transplantation.
Kinch A; Cavelier L; Bengtsson M; Baecklund E; Enblad G; Backlin C; Thunberg U; Sundström C; Pauksens K
Am J Transplant; 2014 Dec; 14(12):2838-45. PubMed ID: 25307322
[TBL] [Abstract][Full Text] [Related]
10. Prognostic analysis for survival in adult solid organ transplant recipients with post-transplantation lymphoproliferative disorders.
Ghobrial IM; Habermann TM; Maurer MJ; Geyer SM; Ristow KM; Larson TS; Walker RC; Ansell SM; Macon WR; Gores GG; Stegall MD; McGregor CG
J Clin Oncol; 2005 Oct; 23(30):7574-82. PubMed ID: 16186599
[TBL] [Abstract][Full Text] [Related]
11. Incidence of post-transplant malignancy among 674 solid-organ-transplant recipients at a single center.
Mihalov ML; Gattuso P; Abraham K; Holmes EW; Reddy V
Clin Transplant; 1996 Jun; 10(3):248-55. PubMed ID: 8826661
[TBL] [Abstract][Full Text] [Related]
12. Post-transplant lymphoproliferative disorders: clinicopathological analysis of 43 cases in a single center, 1990-2009.
Yoon SO; Yu E; Cho YM; Suh C; Kim KM; Han DJ; Lee SG; Huh J
Clin Transplant; 2012; 26(1):67-73. PubMed ID: 21269330
[TBL] [Abstract][Full Text] [Related]
13. Malignancy after solid organ transplantation: an overview.
Zafar SY; Howell DN; Gockerman JP
Oncologist; 2008 Jul; 13(7):769-78. PubMed ID: 18614590
[TBL] [Abstract][Full Text] [Related]
14. Post-transplantation lymphoproliferative disorders localizing in the adenotonsillar region: report from the PTLD.Int survey.
Khedmat H; Taheri S
Ann Transplant; 2011; 16(1):109-16. PubMed ID: 21436784
[TBL] [Abstract][Full Text] [Related]
15. Post-transplant lymphoproliferative disorder after solid-organ transplant in children.
Absalon MJ; Khoury RA; Phillips CL
Semin Pediatr Surg; 2017 Aug; 26(4):257-266. PubMed ID: 28964482
[TBL] [Abstract][Full Text] [Related]
16. Post-transplant malignancy in solid organ transplant recipients in Ireland, The Irish Transplant Cancer Group.
O'Neill JP; Sexton DJ; O'Leary E; O'Kelly P; Murray S; Deady S; Daly F; Williams Y; Dean B; Fitzgerald C; Murad A; Mansoor N; O'Neill JO; Egan J; Houlihan DD; McCormick PA; Morris PG; Ni Raghallaigh S; Little D; Moloney FJ; Conlon PJ
Clin Transplant; 2019 Oct; 33(10):e13669. PubMed ID: 31310037
[TBL] [Abstract][Full Text] [Related]
17. Sebaceous Carcinoma Incidence and Survival Among Solid Organ Transplant Recipients in the United States, 1987-2017.
Sargen MR; Cahoon EK; Lynch CF; Tucker MA; Goldstein AM; Engels EA
JAMA Dermatol; 2020 Dec; 156(12):1307-1314. PubMed ID: 33146669
[TBL] [Abstract][Full Text] [Related]
18. Increased levels of circulating Epstein-Barr virus (EBV)-infected lymphocytes and decreased EBV nuclear antigen antibody responses are associated with the development of posttransplant lymphoproliferative disease in solid-organ transplant recipients.
Riddler SA; Breinig MC; McKnight JL
Blood; 1994 Aug; 84(3):972-84. PubMed ID: 8043879
[TBL] [Abstract][Full Text] [Related]
19. CD-20 expression in post-transplant lymphoproliferative disorders: treatment with rituximab.
Ifthikharuddin JJ; Mieles LA; Rosenblatt JD; Ryan CK; Sahasrabudhe DM
Am J Hematol; 2000 Oct; 65(2):171-3. PubMed ID: 10996837
[TBL] [Abstract][Full Text] [Related]
20. Distinctive Clinicopathologic Features of Monomorphic B-cell Post-transplant Lymphoproliferative Disorders in Children.
Zhang Y; Mariani R; Gong M; Kirschmann D; Caparelli E; Wallace N; Turner R; Lu X; Gao J; Yap KL; Gong S
Pediatr Dev Pathol; 2021; 24(4):318-326. PubMed ID: 33872109
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
